Virios Therapeutics, Inc. (NASDAQ:VIRI – Free Report) – Equities research analysts at HC Wainwright lifted their FY2023 earnings estimates for shares of Virios Therapeutics in a report released on Tuesday, November 14th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($0.29) for the year, up from their prior estimate of ($0.34). The consensus estimate for Virios Therapeutics’ current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Virios Therapeutics’ Q4 2023 earnings at ($0.07) EPS, Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.06) EPS and FY2024 earnings at ($0.21) EPS.
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its earnings results on Monday, November 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04.
Virios Therapeutics Stock Performance
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new position in shares of Virios Therapeutics in the 2nd quarter worth approximately $46,000. State Street Corp increased its stake in shares of Virios Therapeutics by 397.1% in the 2nd quarter. State Street Corp now owns 52,828 shares of the company’s stock valued at $73,000 after acquiring an additional 42,200 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Virios Therapeutics by 144.3% in the 2nd quarter. Geode Capital Management LLC now owns 147,269 shares of the company’s stock valued at $203,000 after acquiring an additional 86,983 shares in the last quarter. Belvedere Trading LLC bought a new stake in shares of Virios Therapeutics in the 2nd quarter valued at $25,000. Finally, McCollum Christoferson Group LLC bought a new stake in shares of Virios Therapeutics in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 10.96% of the company’s stock.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
- Five stocks we like better than Virios Therapeutics
- Energy and Oil Stocks Explained
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- How to Invest in Virtual Reality
- 5 reasons TJX Companies will hit new highs in 2024
- Why Are Stock Sectors Important to Successful Investing?
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.